High materiality7/10
Jefferies Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)
Why it may matterVerify against the original reporting
Buy rating reiterated with a near-term upside implied by the target.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
SNDX received an analyst target update from Jefferies.
- Target $35
- Posted price $17.86
- Analyst firm: Jefferies
- Analyst: Faisal Khurshid
Key facts
- 01
Target: $35
- 02
Posted price: $17.86
- 03
Analyst firm: Jefferies
- 04
Analyst: Faisal Khurshid
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.